SEOUL, South Korea I June 02, 2025 I ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S.

This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing. IMforte [NCT05091567] is a Phase III, open-label, randomized trial evaluating the ...

Preclinical data show that Sail’s eRNA vaccine candidates induce robust anti-malaria immune responses and protect against infection in a mouse challenge model ...

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor ...

PASADENA, CA, USA I June 02, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a ...

NEW YORK, NY, USA and MAINZ, GERMANY I May 28, 2025 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that they ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China ...

PARIS, France and CAMBRIDGE, MA, USA I June 2, 2025 I Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical ...

BASEL, Switzerland I June 1, 2025 I Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety ...

SHANGHAI, China I June 1, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

COPENHAGEN, Denmark I June 2, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and ...

TOKYO, Japan and Cambridge, UK I June 02, 2025 I Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a ...